The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $73.
Altria
MO · a US exchange · USD · Market cap $127.0B · 5,900 employees
Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States.
FAIL · Does not pass the screenPrice as of 17 Nov 2026Daily close, not a live quote
Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price77.46 USD at the 17 Nov 2026 close
- Our value readFair vs our fair value, as of 17 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.69)
- Last reviewed17 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $85.00 to $148.05, base estimate $85.00 (screen dated 2026-11-17).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.69, read 2026-11-13
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Altria holds its Markup at $77.46. Consolidating, no directional conviction, held for 50 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 50 days |
| Price at the screen | $77.46 |
| Valuation | 15.74 trailing · 12.89 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 0.46 |
Five Screens, Shown in Full
Does not pass. Business activity screen
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Business activity: Tobacco | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Altria does not clear the screen at the business-activity stage. It operates in tobacco, so the financial ratios are not the deciding factor here.
Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when MO's ethical verdict changes
Today MO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 17 Nov 2026: it trades at roughly a 9% discount to our $85.00 fair value, 3.60% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-17 screen. The gold marker is the market price at the same screen. A 8.9% discount to the base estimate.
Third-party analyst targets: 11 covering, consensus Hold. The average target sits −6% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & ProjectionsWhere our models see it going: fair-value estimate $85.00, with a range of $85.00 to $148.05, dated to the 2026-11-17 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it is worth knowing
A quality business: 39% profit margins. It trades close to our $85.00 fair value, so the easy discount is gone; you would be paying up for the quality.
| Forward P/E | 12.9xexpensive even after accounting for its growth |
| Trailing P/E | 15.7xreasonably valued |
| EPS, trailing | 4.85 |
| EPS, forward | 5.92 |
| Revenue growth | +3.6%slow but positive growth |
| Profit margin | 39.3%highly profitable on every dollar of sales |
| FCF yield | 5.56% |
| Dividend yield | 5.63% |
| Current ratio | 0.58below 1: short-term bills exceed liquid assets |
| Beta | 0.46barely tracks the market's swings |
| Short interest, float | 0.02% |
| 52-week range | 54.70 - 79.87 |
| Market cap | $127.0B |
| Employees | 5,900 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeMO trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $73.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $70. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $70. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $70. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $70. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $70. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $70. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $70. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $70. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Conagra Cut Its Dividend 50%. The Stock Market Was Warning Investors Yahoo Finance · 14h ago
- Invest $200,000 in These 5 Dividend Stocks to Fund Your Retirement Income Yahoo Finance · 15h ago
- 5 Dividend Stocks Yielding Over 5% to Hide in Your Roth IRA Yahoo Finance · 18h ago
- 5 Huge Dividend Payers the IRS Leaves Alone Inside a Roth Yahoo Finance · 19h ago
- Imperial Brands H2 Earnings Call Highlights Yahoo Finance · 19h ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-14 | SHANKS VIRGINIA E | Director | 2,571 | · | |
| 2026-05-14 | YZAGUIRRE MARIO MAX | Director | 2,571 | · | |
| 2026-05-14 | CLARKE IAN L.T. | Director | 2,571 | · | |
| 2026-05-14 | KELLY-ENNIS DEBRA J | Director | 2,571 | · | |
| 2026-05-14 | DAVIS ROBERT MATTHEWS | Director | 2,571 | · | |
| 2026-05-14 | STRAHLMAN ELLEN | Director | 2,571 | · | |
| 2026-05-14 | CONNELLY MARJORIE MARY | Director | 2,571 | · | |
| 2026-05-14 | STODDART RICHARD S. | Director | 2,571 | · | |
| 2026-05-14 | MCQUADE KATHRYN ANN BOVA | Director | 4,656 | · | |
| 2026-05-13 | MANCUSO SALVATORE | Chief Executive Officer | 40,634 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-11-04 | Gil Cisneros | Democrat | buy | 250K–500K |
| 2026-10-20 | Gil Cisneros | Democrat | buy | 1K–15K |
| 2026-10-19 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-10-15 | Gil Cisneros | Democrat | buy | 50K–100K |
| 2026-10-15 | Ro Khanna | Democrat | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $68.61 | +6.4% | · | $1,064 | +6.4% |
| 2 months | $67.38 | +8.4% | · | $1,084 | +8.4% |
| 3 months | $66.60 | +9.6% | $1.06 | $1,112 | +11.2% |
| 6 months | $56.71 | +28.7% | $2.12 | $1,325 | +32.5% |
| 1 year | $54.71 | +33.5% | $4.20 | $1,411 | +41.1% |
| 2 years | $40.17 | +81.8% | $8.24 | $2,023 | +102.3% |
| 3 years | $35.77 | +104.1% | $12.12 | $2,380 | +138.0% |
| 5 years | $33.72 | +116.5% | $19.40 | $2,740 | +174.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever MO does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.